eXoZymes (EXOZ) and Its Rivals Critical Contrast

eXoZymes (NASDAQ:EXOZ) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its competitors? We will compare eXoZymes to related businesses based on the strength of its institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Earnings and Valuation

This table compares eXoZymes and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
eXoZymes	N/A	-$5.86 million	-16.29
eXoZymes Competitors	$971.75 million	-$41.36 million	9.97

eXoZymes’ competitors have higher revenue, but lower earnings than eXoZymes. eXoZymes is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent recommendations and price targets for eXoZymes and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1	0	0	0	1.00
eXoZymes Competitors	6467	12436	38188	1211	2.59

As a group, “MED – BIOMED/GENE” companies have a potential upside of 51.99%. Given eXoZymes’ competitors stronger consensus rating and higher possible upside, analysts plainly believe eXoZymes has less favorable growth aspects than its competitors.

Institutional & Insider Ownership

51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 72.4% of eXoZymes shares are owned by company insiders. Comparatively, 13.3% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares eXoZymes and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-104.58%	-79.55%
eXoZymes Competitors	-906.16%	-572.54%	-29.84%

Summary

eXoZymes competitors beat eXoZymes on 8 of the 12 factors compared.

About eXoZymes

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.